Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: INIMMUNE CORP
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2021-09-01 to 2023-08-31
Current total value of award: $1836453
Description: EO14042 SBIR TOPIC 091 PHASE II: DEVELOPMENT OF A NEW TLR4 AGONIST FOR THE TREATMENT OF ALLERGIC RHINITIS